mantle cell lymphoma

This page shows the latest mantle cell lymphoma news and features for those working in and with pharma, biotech and healthcare.

Celgene’s Revlimid gets a win in late-stage lymphoma

Celgene is planning to file for approval of Revlimid in the new indication early next year, adding to its current uses in multiple myeloma, mantle cell lymphoma, and anaemia associated with ... An earlier read-out in diffuse large B-cell lymphoma (DLBCL)

Latest news

Another R&D flop for Incyte, but Jakafi keeps delivering

Meanwhile, Incyte was quick to point out that the failure of PI3K delta inhibitor INCB50465 in a form of NHL called diffuse large B cell lymphoma (DLBCL) does not affect phase ... II testing of the drug in other indications, including follicular lymphoma,
AZ expects return to growth this year after 2017 decline

Mantle cell lymphoma therapy Calquence has a long way to go before it can challenge main rival Imbruvica (ibrutinib) from Johnson &Johnson/AbbVie, but according to AZ is picking up 20%
Celgene gains French reimbursement for Revlimid in multiple myeloma

It’s been approved in combination with dexamethasone as a first-line treatment for multiple myeloma in patients who are not eligible for autologous stem cell transplant. ... However, HAS handed Revlimid ASMR V status, equating to ‘no improvement’
Janssen's Imbruvica fails to win NICE backing in lymphoma

Draft guidance from the cost-effectiveness body doesn’t back Imbruvica to treat mantle cell lymphoma (MCL) - an incurable, rare type of B-cell lymphoma that approximately effects 500 people each
AbbVie and Roche plan Venclexta combo filings in leukaemia

AbbVie and Roche have ambitions to extend the use of the drug into non-Hodgkin's lymphoma (NHL) and acute myeloid leukaemia (AML), picking up a breakthrough designation from the FDA ... 8bn last year in CLL, mantle cell lymphoma (MCL), Waldenström

More from news
Approximately 2 fully matching, plus 54 partially matching documents found.

Latest Intelligence

AstraZeneca: building a new ‘open innovation’ pharma company

AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Medical Writer: Salary TBC

Account Director – Health Policy – Global Agency: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Medical Writer: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Account Director, Healthcare Marketing Agency: Salary TBC

Global Business Development Director – Health Education: excellent commission

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Account Director, Medical Education: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Account Manager / Account Director: Competative

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Associate Director: £75, 000-90, 000

Account Director – Healthcare Marketing – Berks: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up: As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...